$AMGN Company News Nasdaq breaks out, reaches

New Post Public Reply Private Reply Replies (0) Message Board

Aug 21, 2014 at 11:49 AM

$AMGN Company News

Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Twitter soars 33% in after hours as results surprise on upside 4:56 p.m. July 29, 2014 - Sue Chang

Lilly psoriasis mAb successful in Phase 3 trial 30 min ago - Seeking Alpha
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog 4:27 p.m. Aug. 20, 2014 - Zacks.com
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog 11:08 a.m. Aug. 20, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: AXP, AMGN, USB 10:29 a.m. Aug. 20, 2014 - TheStreet.com
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog 5:25 p.m. Aug. 19, 2014 - Zacks.com
Right on Target 1:33 p.m. Aug. 19, 2014 - Barrons.com
3 Stocks Pulling The Health Care Sector Downward 1:03 p.m. Aug. 19, 2014 - TheStreet.com
Amgen's thyroid drug meets Phase 3 endpoints 5:51 p.m. Aug. 18, 2014 - Seeking Alpha
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog 5:10 p.m. Aug. 18, 2014 - Zacks.com
Amgen (AMGN) Hits New Lifetime High Today 9:45 a.m. Aug. 18, 2014 - TheStreet.com
RBC’s Top Quintile Quantitative Portfolio Stocks to Buy Now 8:27 a.m. Aug. 18, 2014 - 247WallSt.com
Biotech Stock Mailbag: Exact Sciences, Galena, Amgen 7:22 a.m. Aug. 15, 2014 - TheStreet.com
Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog 5:20 p.m. Aug. 14, 2014 - Zacks.com
Today's Market: Biotech And Technology Names Moving On News 1:33 p.m. Aug. 14, 2014 - Seeking Alpha
Trade-Ideas: Amgen (AMGN) Is Today's "Barbarian At The Gate" Stock 11:17 a.m. Aug. 14, 2014 - TheStreet.com
Amgen Cancer Drug Kyprolis Fails Trial 6:31 p.m. Aug. 13, 2014 - The Wall Street Journal Interactive Edition
Amgen cancer drug fails Phase 3 trial 5:54 p.m. Aug. 13, 2014 - Seeking Alpha
Amgen recalls certain lots of Aranesp 5:38 p.m. Aug. 13, 2014 - Seeking Alpha
After-Hours Trading Shows Amgen (AMGN) Lagging 4:18 p.m. Aug. 13, 2014 - TheStreet.com
3 Stocks Reiterated As A Buy: CAT, BIIB, AMGN 10:29 a.m. Aug. 13, 2014 - TheStreet.com

Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck 9:20 a.m. Aug. 20, 2014 - PR Newswire - PRF
A New Cannabinoid-based Arthritis Therapy in the Making 9:50 a.m. Aug. 19, 2014 - ACCESSWIRE
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 1:55 a.m. Aug. 19, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 5:17 p.m. Aug. 18, 2014 - PR Newswire - PRF
Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy 9:15 a.m. Aug. 14, 2014 - PR Newswire - PRF
Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates 4:12 p.m. Aug. 13, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma 4:01 p.m. Aug. 13, 2014 - PR Newswire - PRF
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs 1:07 p.m. Aug. 11, 2014 - PR Newswire - PRF
Amgen Receives CEO Cancer Gold Standard Accreditation 7:00 a.m. Aug. 11, 2014 - BusinessWire - BZX
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver 9:31 a.m. Aug. 8, 2014 - PR Newswire - PRF
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth 9:13 a.m. Aug. 5, 2014 - PR Newswire - PRF
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 11:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
Earnings Headlines - Amgen 9:30 a.m. Aug. 4, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint 7:30 a.m. Aug. 4, 2014 - PR Newswire - PRF
RBCC 3D Bioprinting Partner Awarded Prestigious Grant 6:54 a.m. July 31, 2014 - BusinessWire - BZX
Resilinc Named 2014 Great Supply Chain Partner by SupplyChainBrain 10:00 a.m. July 30, 2014 - Marketwire
Global Women%s Health Market 2014-2018 6:20 p.m. July 28, 2014 - PR Newswire - PRF
Amgen Announces 2014 Third Quarter Dividend 4:00 p.m. July 25, 2014 - PR Newswire - PRF
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer 2:30 a.m. July 25, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

USFCR Wins 2026 Award for Federal Contracting Services

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

RTI's $14M Boost: A Game-Changer for Tech Innovators

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Deadline Looms for EquipmentShare Investors' Legal Action

Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....

CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

World Fire Congress 2026 Champions Global Fire Safety

Rethinking Fire Safety with a Global Mindset The 2026 World Fire Congress wrapped up in London, signaling a big shift in how we tackle fire safety. Over 60 nations were represented, and they all walked away singing the same tune: if we’re going to handle these ever-mounting fire risks, we have to lean on each other a lot more. Next stop on this crusade? The flashy city...

Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Havoc, CSBC Partner for Autonomous Maritime Future

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Diaper Affordability: A Hidden Crisis, Taxpayer Burden

A Silent Crisis Lurking in Diapers Diapers. We don’t think about them much until we need them, but nearly half of U.S. families are painfully aware of their cost. According to a report from the NDBN Diaper Check 2026, many struggle to meet this basic necessity. This isn't just about keeping babies clean—it's a public health issue with economic ripples Congress can't...